GSK (GSK) News Today GBX 1,448.50 -7.00 (-0.48%) (As of 10/25/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period GSK stays in red for seven straight sessionsOctober 25 at 6:19 PM | msn.comGSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilarOctober 25 at 1:18 PM | finance.yahoo.comGSK pumps up to $800m for US manufacturing site upgradeOctober 25 at 1:18 PM | finance.yahoo.comGSK to invest up to $800M in Pennsylvania siteOctober 25 at 8:17 AM | markets.businessinsider.comGSK plans $800M expansion of Pennsylvania drug manufacturing facilitiesOctober 25 at 8:17 AM | bizjournals.comGSK investing up to $800 million in Lancaster County facility expansionOctober 24 at 10:14 PM | msn.comHaleon: Too Vanilla For My Liking - I See Why GSK & Pfizer Wanted OutOctober 24 at 10:14 PM | seekingalpha.comUBS Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)October 22 at 9:48 PM | markets.businessinsider.comBoston University and GSK collaborate to tackle pulmonary fibrosisOctober 17, 2024 | msn.comGSK rises Thursday, still underperforms marketOctober 17, 2024 | marketwatch.comGSK sues Moderna over mRNA vaccine technologyOctober 16, 2024 | msn.comGSK’s AREXVY Vaccine Shows Promising Results Across Three RSV SeasonsOctober 14, 2024 | msn.comGSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One YearOctober 14, 2024 | finance.yahoo.comGSK’s problem is it has more than one source of painOctober 10, 2024 | ft.comGSK to Resolve 93% of U.S. State Court Zantac Product Liability Cases for Up to $2.2BOctober 9, 2024 | marketwatch.comGSK reaches $2.2bn heartburn medication Zantac settlement in USOctober 9, 2024 | ft.comGSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock SurgesOctober 9, 2024 | finance.yahoo.comGSK to Settle 80,000 Zantac Cases for Up to $2.2 BillionOctober 9, 2024 | msn.comGSK reaches up to $2.2 billion settlement in Zantac US state court casesOctober 9, 2024 | reuters.comGSK Reached Agreements With 10 Plaintiff Firms Over Zantac LitigationOctober 9, 2024 | msn.comGlaxoSmithKline (GSK) Receives a Hold from Goldman SachsOctober 9, 2024 | markets.businessinsider.comGSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV SeasonsOctober 8, 2024 | finance.yahoo.comGSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine ArexvyOctober 8, 2024 | markets.businessinsider.comAnalysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line upOctober 8, 2024 | msn.comJ.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)October 3, 2024 | markets.businessinsider.comGSK’s Arexvy vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in MalaysiaOctober 3, 2024 | msn.comGoldman Sachs Sticks to Their Hold Rating for GlaxoSmithKline (GSK)October 3, 2024 | markets.businessinsider.comGSK plc (NYSE:GSK) Doesn’t Rank Too High In The List Of The Best Global Stocks To BuySeptember 30, 2024 | msn.comGSK plc (LON:GSK) Insider Elizabeth (Liz) McKee Anderson Buys 446 SharesSeptember 25, 2024 | insidertrades.comGSK rises Tuesday, still underperforms marketSeptember 24, 2024 | marketwatch.comGSK: CHMP Issues Positive Opinion On New Fully Liquid Presentation Of Menveo Meningococcal VaccineSeptember 24, 2024 | markets.businessinsider.comAstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nodSeptember 19, 2024 | finance.yahoo.comGSK posts late-stage trial win for co-administered RSV and shingles vaccinesSeptember 18, 2024 | msn.comGSK Settles 2 Cases In California Against ZantacSeptember 18, 2024 | markets.businessinsider.comGSK Reports Positive Data From Co-administration Of RSV And Shingles VaccinesSeptember 18, 2024 | markets.businessinsider.comGSK's RSV, Shingles vaccines show on-par immune response in joint trialSeptember 18, 2024 | msn.comGSK says Blenrep combinations accepted for review in JapanSeptember 17, 2024 | lse.co.ukBrooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles RiskSeptember 16, 2024 | finance.yahoo.comGSK falls Friday, underperforms marketSeptember 14, 2024 | marketwatch.comGSK : Blenrep Combination Receives Breakthrough Therapy Designation For Multiple Myeloma In ChinaSeptember 13, 2024 | markets.businessinsider.comGSK discontinues herpes vaccines; Roivant launches new ‘vant’ around hypertension drugSeptember 11, 2024 | finance.yahoo.comBerenberg Bank Reiterates Buy Rating for GSK (LON:GSK)Berenberg Bank reiterated a "buy" rating and set a GBX 1,820 ($23.80) price objective on shares of GSK in a research note on Tuesday.September 11, 2024 | marketbeat.comGSK reports results from Phase III trials of drug candidate for severe asthmaSeptember 10, 2024 | finance.yahoo.comWith GSK’s share price down 9%, is it time for me to buy more on the dip?September 9, 2024 | uk.finance.yahoo.comGSK antibody drug reduces COPD attacks in trialSeptember 6, 2024 | finance.yahoo.comGSK hails positive results of Nucala clinical trials in lung diseaseSeptember 6, 2024 | lse.co.ukGSK : Phase III Trial Of Nucala In Chronic Obstructive Pulmonary Disease Meets Primary EndpointSeptember 6, 2024 | markets.businessinsider.comGSK's asthma drug Nucala meets main goal in study on treating smoker's lungsSeptember 6, 2024 | msn.comManufacturing operations at GSK will cease after 75 years of delivering medicinesSeptember 5, 2024 | msn.comDeutsche Bank Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)September 3, 2024 | markets.businessinsider.com Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Your Bank Account with THESE 4 Simple Steps (Ad)Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account. Learn these 4 simple steps and protect your savings before it’s too late. GSK Media Mentions By Week GSK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GSK News Sentiment▼0.250.73▲Average Medical News Sentiment GSK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GSK Articles This Week▼86▲GSK Articles Average Week Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AZN News Today HCM News Today GRI News Today ITH News Today INDV News Today BMY News Today GPH News Today IGC News Today PHAR News Today KOD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:GSK) was last updated on 10/25/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredYour financial planner would NEVER tell you thisYour Financial Planner Won't Tell You About This Investment Strategy Silicon Valley insider Jeff Brown has ...Brownstone Research | SponsoredNext opportunity for crypto millions"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive g...Crypto 101 Media | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Hear That Whoosh Sound? It’s the Great Power Suck of 2025”We’re coming to the end of the line for the traditional energy grid. Look what’s happening in California.Traders Agency | SponsoredInvest in the company that won over the DragonsThe pioneer in smart-doorbell technology, RING, pitched their business on the hit show Shark Tank at a valuati...RYSE | SponsoredPutin proposes new currencyRussian leader Vladimir Putin just unveiled the first physical mockup of a proposed new currency. Many spec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
